GLP-1 agonists in HFpEF, DOACs for subclinical AF, renal denervation, and the matter of remaining in the profession are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Obesity and HFpEF
GLP-1 Agonists in HFpEF With Obesity: Are We There Yet? https://www.medscape.com/viewarticle/993980
Wegovy Scores HFpEF Benefits in People With Obesity https://www.medscape.com/viewarticle/995844
- Semaglutide in Obese Patients With HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
- Rationale/Protocol Paper https://doi.org/10.1016/j.jchf.2023.05.010
II. DOAC for Subclinical AF
- NOAH-AFNET 6 Rationale/Protocol https://doi.org/10.1016/j.ahj.2017.04.015
- NOAH-AFNET 6 Trial Results https://www.nejm.org/search?q=NOAH+AFNET
III. Renal Denervation
ReCor Renal Denervation System Safe, Effective: FDA Panel https://www.medscape.com/viewarticle/995741
FDA Panel Split on Efficacy of Spyral Renal Denervation https://www.medscape.com/viewarticle/995800
SPYRAL HTN-ON MED https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00455-X/fulltext
IV. Maintenance of Certification
As MOC Debate Heats Up, Cardiology Societies Weigh In https://www.medscape.com/viewarticle/moc-debate-heated-cardiology-societies-weigh-2023a1000jju
Features
Mandrola's 5 Things to Look for at the Upcoming ESC 2023
https://www.medscape.com/viewarticle/995614
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
This Week in Cardiology